WO2010109115A9 - Composés anticancéreux, leur préparation et leur application en thérapeutique - Google Patents

Composés anticancéreux, leur préparation et leur application en thérapeutique Download PDF

Info

Publication number
WO2010109115A9
WO2010109115A9 PCT/FR2010/050489 FR2010050489W WO2010109115A9 WO 2010109115 A9 WO2010109115 A9 WO 2010109115A9 FR 2010050489 W FR2010050489 W FR 2010050489W WO 2010109115 A9 WO2010109115 A9 WO 2010109115A9
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
therapeutic use
anticancer compounds
anticancer
compounds
Prior art date
Application number
PCT/FR2010/050489
Other languages
English (en)
Other versions
WO2010109115A1 (fr
Inventor
Jérome ARIGON
Claude Bernhart
Monsif Bouaboula
Romain Combet
Samir Jegham
Sandrine Hilairet
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Priority to EP10715954A priority Critical patent/EP2411364A1/fr
Priority to US13/258,921 priority patent/US20120053209A1/en
Priority to JP2012501346A priority patent/JP2012521395A/ja
Publication of WO2010109115A1 publication Critical patent/WO2010109115A1/fr
Publication of WO2010109115A9 publication Critical patent/WO2010109115A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention est relative à des dérivés de nicotinamide pouvant être utilisés comme anticancéreux.
PCT/FR2010/050489 2009-03-24 2010-03-18 Composés anticancéreux, leur préparation et leur application en thérapeutique WO2010109115A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10715954A EP2411364A1 (fr) 2009-03-24 2010-03-18 Composés anticancéreux, leur préparation et leur application en thérapeutique
US13/258,921 US20120053209A1 (en) 2009-03-24 2010-03-18 Anticancer compounds, preparation thereof, and therapeutic use thereof
JP2012501346A JP2012521395A (ja) 2009-03-24 2010-03-18 抗癌化合物、この調製およびこの治療的使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR09/01367 2009-03-24
FR0901367A FR2943675A1 (fr) 2009-03-24 2009-03-24 Composes anticancereux, leur preparation et leur application en therapeutique
FR09/01589 2009-03-31
FR0901589A FR2943671B1 (fr) 2009-03-24 2009-03-31 Composes anticancereux,leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
WO2010109115A1 WO2010109115A1 (fr) 2010-09-30
WO2010109115A9 true WO2010109115A9 (fr) 2011-12-15

Family

ID=41137868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/050489 WO2010109115A1 (fr) 2009-03-24 2010-03-18 Composés anticancéreux, leur préparation et leur application en thérapeutique

Country Status (8)

Country Link
US (1) US20120053209A1 (fr)
EP (1) EP2411364A1 (fr)
JP (1) JP2012521395A (fr)
AR (1) AR075922A1 (fr)
FR (2) FR2943675A1 (fr)
TW (1) TW201038268A (fr)
UY (1) UY32515A (fr)
WO (1) WO2010109115A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013004773B1 (pt) 2010-09-03 2022-05-31 Forma Tm, Llc Compostos, seus usos, e composições para a inibição de nampt
RU2017112522A (ru) 2011-05-04 2019-01-24 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19756261A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
AR075922A1 (es) 2011-05-04
UY32515A (es) 2010-10-29
EP2411364A1 (fr) 2012-02-01
TW201038268A (en) 2010-11-01
FR2943675A1 (fr) 2010-10-01
US20120053209A1 (en) 2012-03-01
WO2010109115A1 (fr) 2010-09-30
FR2943671A1 (fr) 2010-10-01
FR2943671B1 (fr) 2011-05-06
JP2012521395A (ja) 2012-09-13

Similar Documents

Publication Publication Date Title
IL269858A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
ZA201300685B (en) Anticancer derivatives,preparation thereof and therapeutic use thereof
EP2605698A4 (fr) Photopléthysmographie de site central, administration de médicament et sécurité
IL239639A0 (en) A modified spiropyrido {1,2-a} pyrazine derivative and its medicinal use as an HIV integrase inhibitor
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
IL215285A0 (en) Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs
WO2012019426A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
IL221952A (en) Annotations 2, 3-Dihydro-1h - Indene-1-Il-7,2- Diazaspiro [5.3] Noonan and Pharmaceuticals Containing Them
WO2012019430A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
IL225824A0 (en) History of quinoxaline, their preparation and pharmaceutical preparations containing them
PL2655375T3 (pl) Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie
ZA201209739B (en) Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof
IL209593A (en) Diamino-Pyridine, Pyrimidine and Pyridazine Derivatives, Pharmaceutical Preparations Containing Them and Uses as Modulators of Histamine H4 Receptor
EP2562172A4 (fr) Dérivés de sphaélactone, leurs compositions pharmaceutiques, leurs méthodes de synthèse et leurs applications
IL226094A0 (en) The history of pyrazine, their preparation and pharmaceutical preparations containing them
WO2011141488A3 (fr) Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
AP2012006292A0 (en) Topical use of hydroxytyrosol and derivatives for the prevention of HIV infection.
EP2386553A4 (fr) Dérivés de benzimidazole-4-carboxamide, leurs procédés d'élaboration, compositions pharmaceutiques et leurs utilisations
WO2012024350A3 (fr) Adénovirus anticancéreux
WO2010115125A3 (fr) Composition à base de 2,4,6-trifluoro-n-[6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide
WO2011107866A3 (fr) Dérivés silyliques de polysaccharides
IL225823A0 (en) History of quinazoline, their preparation and pharmaceutical preparations containing them
EP2403497A4 (fr) Composés, compositions et utilisation pour une thérapie anticancéreuse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10715954

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012501346

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010715954

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13258921

Country of ref document: US